<?xml version="1.0" encoding="UTF-8"?>
<results title="funders">
 <result pre="+44 1223 334048 es336@cam.ac.uk [], 0000000121885934 grid.5335.0 Department of Pharmacology," exact="University of Cambridge," post="epub: 2017-10-10 pmc-release: 2017-10-10 ppub: 2018 265 2 231"/>
 <result pre="pain Nociceptor Optogenetics Voltage gated sodium channel (NaV) Funding http://dx.doi.org/10.13039/501100000341" exact="Arthritis Research UK" post="20930 St. John Smith Ewan http://dx.doi.org/10.13039/501100000833 Rosetrees Trust A1296"/>
 <result pre="http://dx.doi.org/10.13039/501100000341 Arthritis Research UK 20930 St. John Smith Ewan http://dx.doi.org/10.13039/501100000833" exact="Rosetrees Trust" post="A1296 St. John Smith Ewan Introduction Nociception is the"/>
 <result pre="as targets for novel analgesics. Acknowledgements I acknowledge funding from" exact="Arthritis Research UK" post="(Grant Reference 20930) and the Rosetrees Trust (Grant Reference"/>
 <result pre="funding from Arthritis Research UK (Grant Reference 20930) and the" exact="Rosetrees Trust" post="(Grant Reference A1296), which support pain research in my"/>
 <result pre="28969375 39. RST-001 phase I/II trial for advanced retinitis pigmentosa." exact="Allergan" post="(2015). https://clinicaltrials.gov/ct2/show/NCT02556736 40. Melzack R Wall PD Pain mechanisms:"/>
</results>
